RxDoctor Payments Data

Daniel Bouknight, MD

Cardiovascular Disease · Irmo, SCNPI 1427057009

Payments from drug & device makers

$9,779in general payments, 2019–2025

Across 467 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Lantheus Medical Imaging, Inc.$972
  • AstraZeneca$563
  • Pfizer$434
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,76490%
  • Education$430%
  • Other$97210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,779 in reported general payments places this provider in the 70th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$996,121
Medicare patients
1,372
Services billed
8,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan256$268,330
EliquisApixaban206$184,935
XareltoRivaroxaban155$140,470
Repatha SureclickEvolocumab120$101,607
JardianceEmpagliflozin55$41,652
MounjaroTirzepatide15$15,295
Repatha SyringeEvolocumab13$7,331
Ranolazine ErRanolazine72$7,327
Rosuvastatin Calcium236$5,693
Metoprolol Succinate246$4,641
Dexlansoprazole DrDexlansoprazole15$4,132
Losartan Potassium191$3,522
Nebivolol Hcl31$3,510
ClopidogrelClopidogrel Bisulfate202$2,944
Olmesartan Medoxomil41$2,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,353$268,330256 claims
PfizerEliquis$434$184,935206 claims
Johnson & JohnsonXarelto$1,078$140,470155 claims
Boehringer IngelheimJardiance$320$41,65255 claims
Lilly USA, LLCMounjaro$14$15,29515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Irmo

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →